polidocanol + detalimogene voraplasmid

polidocanol + detalimogene voraplasmid is an investigational combination therapy consisting of a polidocanol surfactant bladder rinse followed by the intravesical administration of detalimogene voraplasmid (EG-70), a non-viral gene therapy. Developed by enGene, this combination is being evaluated for the treatment of patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Detalimogene voraplasmid is a plasmid-based therapy delivered via enGene's proprietary Dually Derivatized Oligochitosan (DDX) nanoparticle platform. The plasmid encodes human interleukin-12 (IL-12) to stimulate adaptive immunity and two double-stranded RNA (dsRNA) activators of retinoic acid-inducible gene I (RIG-I) to stimulate innate immunity. Polidocanol is administered as a 0.25% surfactant bladder rinse prior to the gene therapy to enhance the penetration, distribution, and transfection efficiency of the detalimogene voraplasmid nanoparticles within the bladder urothelium, significantly boosting localized IL-12 expression and antitumor activity.